A phase Ib, multicenter, open-label study of the antibody-drug conjugate trastuzumab deruxtecan (DS-8201a) combination with nivolumab for advanced HER2-expressing breast or urothelial cancer

被引：0

作者：

Hurvitz, S. A. ^{[1
]}

Galsky, M. D. ^{[2
]}

Shahidi, J. ^{[3
]}

Zhang, G. ^{[4
]}

Raza, S. ^{[3
]}

Necchi, A. ^{[5
]}

机构：

[1] UCLA Med Ctr, Dept Med, Los Angeles, CA USA

[2] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA

[3] Daiichi Sankyo Inc, Clin Dev, Basking Ridge, NJ USA

[4] Daiichi Sankyo Inc, Biostat & Data Management, Basking Ridge, NJ USA

[5] Fdn IRCCS Ist Nazl Tumori, Med Oncol, Milan, Italy

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

370TiP

引用

页数：1

共 50 条

[21] A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
Siena, Salvatore
Di Bartolomeo, Maria
Raghav, Kanwal Pratap Singh
Masuishi, Toshiki
Loupakis, Fotios
Kawakami, Hisato
Yamaguchi, Kensei
Nishina, Tomohiro
Fakih, Marwan
Elez, Elena
Rodriguez, Javier
Ciardiello, Fortunato
Saxena, Kapil
Yamamoto, Eriko
Bako, Emarjola
Okuda, Yasuyuki
Shahidi, Javad
Grothey, Axel
Yoshino, Takayuki
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[22] A phase III, multicenter, randomized, open label trial of [fam-] trastuzumab deruxtecan (DS-8201a) versus investigator's choice in HER2-low breast cancer.
Modi, Shanu
Ohtani, Shoichiro
Lee, Caleb C.
Wang, Kongming
Saxena, Kapil
Cameron, David A.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[23] Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
Tamura, Kenji
Tsurutani, Junji
Takahashi, Shunji
Iwata, Hiroji
Krop, Ian E.
Redfern, Charles
Sagara, Yasuaki
Doi, Toshihiko
Park, Haeseong
Murthy, Rashmi K.
Redman, Rebecca A.
Jikoh, Takahiro
Lee, Caleb
Sugihara, Masahiro
Shahidi, Javad
Yver, Antoine
Modi, Shanu
LANCET ONCOLOGY, 2019, 20 (06): : 816 - 826
[24] Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
Shitara, Kohei
Iwata, Hiroji
Takahashi, Shunji
Tamura, Kenji
Park, Haeseong
Modi, Shanu
Tsurutani, Junji
Kadowaki, Shigenon
Yamaguchi, Kensei
Iwasa, Satoru
Saito, Kaku
Fujisaki, Yoshihiko
Sugihara, Masahiro
Shahidi, Javad
Doi, Toshihiko
LANCET ONCOLOGY, 2019, 20 (06): : 827 - 836
[25] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01)
Yoshino, Takayuki
Di Bartolomeo, Maria
Raghav, Kanwal Pratap Singh
Masuishi, Toshiki
Kawakami, Hisato
Yamaguchi, Kensei
Nishina, Tomohiro
Wainberg, Zev A.
Elez, Elena
Rodriguez, Javier
Fakih, Marwan
Ciardiello, Fortunato
Saxena, Kapil
Kobayashi, Kojiro
Bako, Emarjola
Okuda, Yasuyuki
Meinhardt, Gerold
Grothey, Axel
Siena, Salvatore
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[26] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).
Yoshino, Takayuki
Di Bartolomeo, Maria
Raghav, Kanwal Pratap Singh
Masuishi, Toshiki
Loupakis, Fotios
Kawakami, Hisato
Yamaguchi, Kensei
Nishina, Tomohiro
Wainberg, Zev A.
Elez, Elena
Rodriguez, Javier
Fakih, Marwan
Ciardiello, Fortunato
Saxena, Kapil
Kobayashi, Kojiro
Bako, Emarjola
Okuda, Yasuyuki
Meinhardt, Gerold
Grothey, Axel
Siena, Salvatore
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[27] Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2
Mutlu, Levent
McNamara, Blair
Bellone, Stefania
Manavella, Diego D.
Demirkiran, Cem
Greenman, Michelle
Verzosa, Miguel Skyler Z.
Buza, Natalia
Hui, Pei
Hartwich, Tobias Max Philipp
Harold, Justin
Yang-Hartwich, Yang
Zipponi, Margherita
Altwerger, Gary
Ratner, Elena
Huang, Gloria S.
Clark, Mitchell
Andikyan, Vaagn
Azodi, Masoud
Schwartz, Peter E.
Santin, Alessandro D.
CLINICAL & EXPERIMENTAL METASTASIS, 2024, 41 (05) : 765 - 775
[28] Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC)
Siena, S.
Raghav, K.
Masuishi, T.
Yamaguchi, K.
Nishina, T.
Elez, E.
Rodriguez, J.
Chau, I.
Di Bartolomeo, M.
Kawakami, H.
Suto, F.
Kobayashi, K.
Koga, M.
Inaki, K.
Kuwahara, Y.
Takehara, I.
Grothey, A.
Yoshino, T.
ANNALS OF ONCOLOGY, 2021, 32 : S532 - S532
[29] Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.
Iwata, Hiroji
Tamura, Kenji
Doi, Toshihiko
Tsurutani, Junji
Modi, Shanu
Park, Haeseong
Krop, Ian E.
Sagara, Yasuaki
Redfern, Charles H.
Murthy, Rashmi Krishna
Redman, Rebecca A.
Shitara, Kohei
Fujisaki, Yoshihiko
Sugihara, Masahiro
Zhang, Lin
Shahidi, Javad
Yver, Antoine
Takahashi, Shunji
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[30] Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).
Galsky, Matt D.
Del Conte, Gianluca
Foti, Silvia
Yu, Evan Y.
Machiels, Jean-Pascal H.
Doger, Bernard
Necchi, Andrea
De Braud, Filippo G.
Hamilton, Erika P.
Hennequin, Audrey
Van den Mooter, Tom
Debruyne, Philip R.
Moreno, Irene
Arkenau, Hendrik-Tobias
Tsuchihashi, Zenta
Cheng, Fu-Chih
Augustine, Bincy
Cheng, Ben
Barrios, Daniel
Luftner, Diana
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)

← 1 2 3 4 5 →